Neja Šamec

456 total citations
18 papers, 302 citations indexed

About

Neja Šamec is a scholar working on Molecular Biology, Genetics and Cancer Research. According to data from OpenAlex, Neja Šamec has authored 18 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 6 papers in Genetics and 6 papers in Cancer Research. Recurrent topics in Neja Šamec's work include Glioma Diagnosis and Treatment (6 papers), Extracellular vesicles in disease (5 papers) and RNA Interference and Gene Delivery (4 papers). Neja Šamec is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Extracellular vesicles in disease (5 papers) and RNA Interference and Gene Delivery (4 papers). Neja Šamec collaborates with scholars based in Slovenia, Belgium and Russia. Neja Šamec's co-authors include Alja Zottel, Ivana Jovčevska, Radovan Komel, Alja Videtič Paska, Jernej Mlakar, Maxim Sorokin, Anton Buzdin, Jernej Šribar, Igor Križaj and Rok Romih and has published in prestigious journals such as International Journal of Molecular Sciences, Molecules and Oncotarget.

In The Last Decade

Neja Šamec

17 papers receiving 302 citations

Peers

Neja Šamec

GENET

IMMUN

Alja Zottel Slovenia

Wojciech Szopa Poland

Yangong Zhang China

Julie Sesen United States

Kathrin A. Schmohl Germany

Billy Samuel Hill Italy

Amber B. Jones United States

Eskil Eskilsson United States

Laure Malric France

Rosalie Schnoor Netherlands

Alja Zottel Slovenia

Neja Šamec

243 ×1.2

127 ×1.0

84 ×1.2

GENET

112 ×2.4

47 ×1.1

IMMUN

Citations per year, relative to Neja Šamec Neja Šamec (= 1×) peers Alja Zottel

Countries citing papers authored by Neja Šamec

Since Specialization

Citations

This map shows the geographic impact of Neja Šamec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neja Šamec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neja Šamec more than expected).

Fields of papers citing papers by Neja Šamec

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neja Šamec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neja Šamec. The network helps show where Neja Šamec may publish in the future.

Co-authorship network of co-authors of Neja Šamec

This figure shows the co-authorship network connecting the top 25 collaborators of Neja Šamec. A scholar is included among the top collaborators of Neja Šamec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neja Šamec. Neja Šamec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Zottel, Alja, Neja Šamec, & Ivana Jovčevska. (2025). <i>TNFSF14 </i>and <i>CD44</i> are overexpressed in glioblastoma and associated with immunosuppressive microenvironment. Biomolecules and Biomedicine. 25(8). 1829–1843.

Šamec, Neja, et al.. (2025). From Biomarker Discovery to Clinical Applications of Metabolomics in Glioblastoma. Metabolites. 15(5). 295–295. 1 indexed citations

Šamec, Neja, Alja Zottel, Jernej Šribar, et al.. (2025). In Vitro Functional Validation of an Anti-FREM2 Nanobody for Glioblastoma Cell Targeting. Antibodies. 14(1). 8–8. 2 indexed citations

Zottel, Alja, Metka Novak, Neja Šamec, et al.. (2023). Anti-Vimentin Nanobody Decreases Glioblastoma Cell Invasion In Vitro and In Vivo. Cancers. 15(3). 573–573. 8 indexed citations

Zottel, Alja, Ivana Jovčevska, & Neja Šamec. (2023). Non-animal glioblastoma models for personalized treatment. Heliyon. 9(10). e21070–e21070. 4 indexed citations

Jovčevska, Ivana, et al.. (2023). Sonication is a suitable method for loading nanobody into glioblastoma small extracellular vesicles. Heliyon. 9(5). e15674–e15674. 12 indexed citations

Zolotovskaia, Marianna, Victor Tkachev, Maxim Sorokin, et al.. (2021). Algorithmically Deduced FREM2 Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas. Cancers. 13(16). 4117–4117. 12 indexed citations

Zottel, Alja, Ivana Jovčevska, Neja Šamec, & Radovan Komel. (2021). Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. Critical Reviews in Oncology/Hematology. 160. 103283–103283. 24 indexed citations

Sorokin, Maxim, Alja Zottel, Neja Šamec, et al.. (2021). Large-Scale Transcriptomics-Driven Approach Revealed Overexpression of CRNDE as a Poor Survival Prognosis Biomarker in Glioblastoma. Cancers. 13(14). 3419–3419. 14 indexed citations

10.

Novak, Metka, Barbara Breznik, Bernarda Majc, et al.. (2021). TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell Invasion. Molecules. 26(17). 5141–5141. 21 indexed citations

11.

Zottel, Alja, Neja Šamec, Ivana Jovčevska, et al.. (2021). Current Technologies for RNA-Directed Liquid Diagnostics. Cancers. 13(20). 5060–5060. 21 indexed citations

12.

Zottel, Alja, Ivana Jovčevska, Neja Šamec, et al.. (2020). Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration. Therapeutic Advances in Medical Oncology. 12. 3863530342–3863530342. 29 indexed citations

13.

Šamec, Neja, Alja Zottel, Alja Videtič Paska, & Ivana Jovčevska. (2020). Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma. Molecules. 25(3). 490–490. 34 indexed citations

14.

Zottel, Alja, Neja Šamec, Pia Pužar Dominkuš, et al.. (2020). Analysis of miR-9-5p, miR-124-3p, miR-21-5p, miR-138-5p, and miR-1-3p in Glioblastoma Cell Lines and Extracellular Vesicles. International Journal of Molecular Sciences. 21(22). 8491–8491. 38 indexed citations

15.

Zottel, Alja, Neja Šamec, Alja Videtič Paska, & Ivana Jovčevska. (2020). Coding of Glioblastoma Progression and Therapy Resistance through Long Noncoding RNAs. Cancers. 12(7). 1842–1842. 30 indexed citations

16.

Jovčevska, Ivana, Alja Zottel, Neja Šamec, et al.. (2019). High FREM2 Gene and Protein Expression Are Associated with Favorable Prognosis of IDH-WT Glioblastomas. Cancers. 11(8). 1060–1060. 20 indexed citations

17.

Šamec, Neja, Ivana Jovčevska, Jure Stojan, et al.. (2018). Glioblastoma-specific anti-TUFM nanobody for in-vitro immunoimaging and cancer stem cell targeting. Oncotarget. 9(25). 17282–17299. 20 indexed citations

18.

Jovčevska, Ivana, Neja Šamec, Alja Zottel, et al.. (2018). Meta-Analysis and Experimental Validation Identified FREM2 and SPRY1 as New Glioblastoma Marker Candidates. International Journal of Molecular Sciences. 19(5). 1369–1369. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact